TABLE 2.
Agreement of Xpert Xpress SARS-CoV-2 test and comparator RT-PCR tests
| Comparator (targets) | No. of results (Xpert/comparator)a
|
PPAb (95% CI) | NPAc (95% CI) | |||
|---|---|---|---|---|---|---|
| Pos/Pos | Pos/Neg | Neg/Pos | Neg/Neg | |||
| All methods | 219 | 11 | 1 | 250 | 99.5 (97.5–99.9) | 95.8 (92.6–97.6) |
| Quest SARS-CoV-2 rRT-PCR (N1, N3) | 12 | 0 | 1 | 75 | 92.3 (66.7–98.6) | 100 (95.1–100) |
| RealStar SARS-CoV-2 RT-PCR kit 1.0 (S, E) | 60 | 0 | 0 | 69 | 100 (94.0–100) | 100 (94.7–100) |
| New York SARS-CoV-2 real-time RT- PCR diagnostic panel (N1, N2) | 74 | 2 | 0 | 23 | 100 (94.2–100) | 92.0 (75.0–97.8) |
| Inhouse (RdRp) | 30 | 9 | 0 | 26 | 100 (88.7–100) | 74.3(57.9–85.8) |
| Allplex 2019-nCoV assay, GeneFinder COVID-19 Plus RealAmp kit (E, N, RdRp) | 35 | 0 | 0 | 44 | 100 (90.1–100) | 100 (92.0–100) |
| Abbott RealTime SARS-CoV-2 assay (N, RdRp) | 8 | 0 | 0 | 10 | 100 (67.6–100) | 100 (77.2–100) |
| Simplexa COVID-19 direct (ORF1ab, S) | 0 | 0 | 0 | 3 | 100 (43.9–100) | |
a
Pos, positive; Neg, negative.
b
PPA, positive percent agreement {[Pos/Pos ÷ (Pos/Pos + Neg/Pos)] × 100}.
c
NPA, negative percent agreement {[Neg/Neg ÷ (Neg/Neg + Pos/Neg)] × 100}.